Hy BioPharma Inc.
This article was originally published in Start Up
Executive Summary
Hy BioPharma is developing hypericin phototherapeutics for cancers and autoimmune disorders. The Israeli/US start-up is also in Phase I/IIb trials for an oral formulation of hypericin for possible use in combination therapy with Temodar for the treatment of glioblastoma.
You may also be interested in...
Start-Up Previews (07/2008)
A preview of the emerging health care companies profiled in the current, all-profiles issue of Start-Up. This month's profile groups are "Glioblastoma Start-Ups Get Specific," "Glaucoma Start-Ups Reach Critical Mass," and "ALS on the Cusp." Plus these Start-Ups Across Health Care: EarlySense, NeoChord, and Pantec Biosolutions.
Glioblastoma Start-Ups Get Specific
For start-ups developing novel and risky medicines to treat glioblastoma, a rare, invasive form of brain cancer, the Pfizer/Avant deal was a watershed moment: It signaled the vigorous interest of a pharmaceutical behemoth in a disease where patients number in just the tens of thousands. The positive effects are likely to be felt in executive suites of biotechs developing therapeutics for this grievous disease.
MedGenesis Therapeutix Inc.
MedGenesis Therapeutix is developing convection-enhanced delivery, a technique that involves infusion under positive pressure of a drug to specific locations of the brain. The leading indication for its CED technology is glioblastoma.